BTK and B-cell non-Hodgkin lymphoma: Moreover, the administration of another BTK inhibitor, acalabrutinib, in canine B-cell lymphoma in vitro and in vivo models resulted in dose-dependent inhibition of BTK autophosphorylation and clinical benefit in 30% of the dogs [9].